{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T04:10:05Z","timestamp":1751688605958,"version":"3.41.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The prevalence of obesity is rapidly increasing worldwide, however there is a notable gap in understanding how obesity affects the pharmacokinetics of drugs and how dosing should be adjusted in obese population. The goals of this work were to evaluate plasma pharmacokinetics and tissue disposition of piperacillin, cefazolin, and cefoxitin in a rat model of diet-induced obesity compared to a lean cohort. Male Long-Evans rats were fed high-fat or control diets for 23 weeks. Various measures of body size and composition were collected. The animals were administered a mixture containing 50 mg\/kg cefoxitin, 50 mg\/kg cefazolin, and 120 mg\/kg piperacillin. Plasma and tissues were collected and analyzed using a validated LC-MS\/MS method. Whole-body physiologically-based pharmacokinetic (PBPK) models were develop to capture the biodistribution of these drugs in lean and obese cohorts.\u00a0Most plasma and tissue concentrations were comparable between lean and obese rats after dosing based on mg\/kg of total body weight; however, in some tissues concentration was consistently higher in obese animals. PBPKs successfully captured biodistribution of three drugs and both cohorts; however, cohort-specific (lean or obese) parameters were required for liver (for cefoxitin and cefazolin) and spleen (for all three drugs) for capturing the data.The results support the necessity of using mg\/kg dosing for obese rats to achieve drug exposure comparable to that of lean rats. In the future, these models could be extended to predict plasma pharmacokinetics\u00a0and tissue disposition of cefoxitin, cefazolin, and piperacillin in humans  by incorporating interspecies scaling approaches.<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical Abstract<\/jats:bold>\n          <\/jats:p>","DOI":"10.1208\/s12248-025-01063-4","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T15:20:14Z","timestamp":1744903214000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Physiologically Based Modeling of Cefoxitin, Cefazolin, and Piperacillin Pharmacokinetics in Obese and Lean Rats"],"prefix":"10.1208","volume":"27","author":[{"given":"Yi-Hua","family":"Sheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Kosicka-Noworzy\u0144","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Siemi\u0105tkowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sijia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karan","family":"Sapra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian","family":"Awad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justine","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Doss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Yohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3863-4757","authenticated-orcid":false,"given":"Leonid","family":"Kagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"1063_CR1","unstructured":"Obesity and overweight. World Health Organization (WHO). 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight. Accessed 24 Nov 2024."},{"key":"1063_CR2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s40005-013-0073-4","volume":"43","author":"S-J Cho","year":"2013","unstructured":"Cho S-J, Yoon I-S, Kim D-D. Obesity-related physiological changes and their pharmacokinetic consequences. J Pharm Investig. 2013;43:161\u20139.","journal-title":"J Pharm Investig"},{"issue":"1","key":"1063_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1021\/js980173a","volume":"88","author":"RA Blouin","year":"1999","unstructured":"Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci. 1999;88(1):1\u20137.","journal-title":"J Pharm Sci"},{"issue":"11","key":"1063_CR4","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1200\/JCO.1996.14.11.3000","volume":"14","author":"GL Rosner","year":"1996","unstructured":"Rosner GL, Hargis JB, Hollis DR, Budman DR, Weiss RB, Henderson IC, et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol. 1996;14(11):3000\u20138.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1063_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2146\/ajhp120568","volume":"70","author":"DW Bratzler","year":"2013","unstructured":"Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70(3):195\u2013283.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"1063_CR6","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.clinthera.2015.11.009","volume":"38","author":"L Brunetti","year":"2016","unstructured":"Brunetti L, Kagan L, Forrester G, Aleksunes LM, Lin H, Buyske S, et al. Cefoxitin plasma and subcutaneous adipose tissue concentration in patients undergoing sleeve gastrectomy. Clin Ther. 2016;38(1):204\u201310.","journal-title":"Clin Ther"},{"issue":"1","key":"1063_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003495-197917010-00001","volume":"17","author":"RN Brogden","year":"1979","unstructured":"Brogden RN, Heel RC, Speight TM, Avery GS. Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1979;17(1):1\u201337.","journal-title":"Drugs"},{"issue":"4","key":"1063_CR8","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1128\/AAC.4.4.396","volume":"4","author":"MG Bergeron","year":"1973","unstructured":"Bergeron MG, Brusch JL, Barza M, Weinstein L. Bactericidal activity and pharmacology of cefazolin. Antimicrob Agents Chemother. 1973;4(4):396\u2013401.","journal-title":"Antimicrob Agents Chemother"},{"key":"1063_CR9","first-page":"1607","volume":"1","author":"T Kusaba","year":"2009","unstructured":"Kusaba T. Safety and efficacy of cefazolin sodium in the management of bacterial infection and in surgical prophylaxis. Clinical Medicine: Therapeutics. 2009;1:1607\u201315.","journal-title":"Clinical Medicine: Therapeutics"},{"issue":"6","key":"1063_CR10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/j.1875-9114.1982.tb03202.x","volume":"2","author":"CL Fortner","year":"1982","unstructured":"Fortner CL, Finley RS, Schimpff SC. Piperacillin sodium: antibacterial spectrum, pharmacokinetics, clinical efficacy, and adverse reactions. Pharmacotherapy: J Human Pharmacol Drug Ther. 1982;2(6):287\u201398.","journal-title":"Pharmacotherapy: J Human Pharmacol Drug Ther."},{"key":"1063_CR11","doi-asserted-by":"publisher","first-page":"116259","DOI":"10.1016\/j.jpba.2024.116259","volume":"248","author":"YH Sheng","year":"2024","unstructured":"Sheng YH, Siemiatkowska A, Kosicka-Noworzyn K, Brunetti L, Kagan L. A validated LC-MS\/MS method for simultaneous quantitation of piperacillin, cefazolin, and cefoxitin in rat plasma and twelve tissues. J Pharm Biomed Anal. 2024;248:116259.","journal-title":"J Pharm Biomed Anal"},{"issue":"7","key":"1063_CR12","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1023\/A:1018943613122","volume":"10","author":"B Davies","year":"1993","unstructured":"Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10(7):1093\u20135.","journal-title":"Pharm Res"},{"issue":"4","key":"1063_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1177\/074823379701300401","volume":"13","author":"RP Brown","year":"1997","unstructured":"Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health. 1997;13(4):407\u201384.","journal-title":"Toxicol Ind Health"},{"issue":"1","key":"1063_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12020-017-1403-5","volume":"58","author":"M Aslam","year":"2017","unstructured":"Aslam M, Madhu SV. Development of metabolic syndrome in high-sucrose diet fed rats is not associated with decrease in adiponectin levels. Endocrine. 2017;58(1):59\u201365.","journal-title":"Endocrine"},{"issue":"2","key":"1063_CR15","doi-asserted-by":"publisher","first-page":"R266","DOI":"10.1152\/ajpregu.1984.247.2.R266","volume":"247","author":"DL Crandall","year":"1984","unstructured":"Crandall DL, Goldstein BM, Gabel RA, Cervoni P. Hemodynamic effects of weight reduction in the obese rat. Am J Physiol-Regul, Integr Comp Physiol. 1984;247(2):R266\u201371.","journal-title":"Am J Physiol-Regul, Integr Comp Physiol"},{"issue":"1","key":"1063_CR16","doi-asserted-by":"publisher","first-page":"R46","DOI":"10.1152\/ajpregu.1984.247.1.R46","volume":"247","author":"DL Crandall","year":"1984","unstructured":"Crandall DL, Goldstein BM, Huggins F, Cervoni P. Adipocyte blood flow: influence of age, anatomic location, and dietary manipulation. Am J Physiol-Regul, Integr Comp Physiol. 1984;247(1):R46\u201351.","journal-title":"Am J Physiol-Regul, Integr Comp Physiol"},{"issue":"2","key":"1063_CR17","doi-asserted-by":"publisher","first-page":"R314","DOI":"10.1152\/ajpregu.1986.251.2.R314","volume":"251","author":"DL Crandall","year":"1986","unstructured":"Crandall DL, Goldstein BM, Lizzo FH, Gabel RA, Cervoni P. Hemodynamics of obesity: influence of pattern of adipose tissue cellularity. Am J Physiol-Regul, Integr Comp Physiol. 1986;251(2):R314\u20139.","journal-title":"Am J Physiol-Regul, Integr Comp Physiol"},{"issue":"6","key":"1063_CR18","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/jac\/42.6.769","volume":"42","author":"T Dalla Costa","year":"1998","unstructured":"Dalla Costa T, Nolting A, Kovar A, Derendorf H. Determination of free interstitial concentrations of piperacillin-tazobactam combinations by microdialysis. J Antimicrob Chemother. 1998;42(6):769\u201378.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"1063_CR19","doi-asserted-by":"publisher","first-page":"H1495","DOI":"10.1152\/ajpheart.00478.2012","volume":"304","author":"V Nagarajan","year":"2013","unstructured":"Nagarajan V, Gopalan V, Kaneko M, Angeli V, Gluckman P, Richards AM, et al. Cardiac function and lipid distribution in rats fed a high-fat diet: in vivo magnetic resonance imaging and spectroscopy. Am J Physiol-Heart Circ Physiol. 2013;304(11):H1495\u2013504.","journal-title":"Am J Physiol-Heart Circ Physiol"},{"issue":"5","key":"1063_CR20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/10739680600745919","volume":"13","author":"R Prakash","year":"2006","unstructured":"Prakash R, Mintz JD, Stepp DW. Impact of obesity on coronary microvascular function in the Zucker rat. Microcirculation. 2006;13(5):389\u201396.","journal-title":"Microcirculation"},{"issue":"2","key":"1063_CR21","doi-asserted-by":"publisher","first-page":"R228","DOI":"10.1152\/ajpregu.1987.253.2.R228","volume":"253","author":"DB West","year":"1987","unstructured":"West DB, Prinz WA, Francendese AA, Greenwood M. Adipocyte blood flow is decreased in obese Zucker rats. Am J Physiol-Regul, Integr Comp Physiol. 1987;253(2):R228\u201333.","journal-title":"Am J Physiol-Regul, Integr Comp Physiol"},{"issue":"8","key":"1063_CR22","doi-asserted-by":"publisher","first-page":"786","DOI":"10.2337\/diab.26.8.786","volume":"26","author":"PD Lucas","year":"1977","unstructured":"Lucas PD, Foy JM. Effects of experimental diabetes and genetic obesity on regional blood flow in the rat. Diabetes. 1977;26(8):786\u201392.","journal-title":"Diabetes"},{"issue":"5","key":"1063_CR23","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1152\/jappl.1998.85.5.1813","volume":"85","author":"MD Delp","year":"1998","unstructured":"Delp MD, Evans MV, Duan C. Effects of aging on cardiac output, regional blood flow, and body composition in Fischer-344 rats. J Appl Physiol. 1998;85(5):1813\u201322.","journal-title":"J Appl Physiol"},{"issue":"5","key":"1063_CR24","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1128\/AAC.28.5.654","volume":"28","author":"IA Bakker-Woudenberg","year":"1985","unstructured":"Bakker-Woudenberg IA, van den Berg JC, Vree TB, Baars AM, Michel MF. Relevance of serum protein binding of cefoxitin and cefazolin to their activities against Klebsiella pneumoniae pneumonia in rats. Antimicrob Agents Chemother. 1985;28(5):654\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4 Suppl B","key":"1063_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/jac\/4.suppl_B.69","volume":"1978","author":"J Schrogie","year":"1978","unstructured":"Schrogie J, Davies R, Yeb K, Rogers D, Holmes G, Skeggs H, et al. Bioavailability and pharmacokinetics of cefoxitin sodium. J Antimicrob Chemother. 1978;1978(4 Suppl B):69\u201378.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"1063_CR26","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1128\/AAC.17.2.188","volume":"17","author":"FH Lee","year":"1980","unstructured":"Lee FH, Pfeffer M, Van Harken DR, Smyth RD, Hottendorf GH. Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans. Antimicrob Agents Chemother. 1980;17(2):188\u201392.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1063_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1021\/js950304x","volume":"85","author":"A Nolting","year":"1996","unstructured":"Nolting A, Dalla Costa T, Vistelle R, Rand KH, Derendorf H. Determination of free extracellular concentrations of piperacillin by microdialysis. J Pharm Sci. 1996;85(4):369\u201372.","journal-title":"J Pharm Sci"},{"key":"1063_CR28","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s10928-018-9586-9","volume":"45","author":"X Zang","year":"2018","unstructured":"Zang X, Kagan L. Physiologically-based modeling and interspecies prediction of paclitaxel pharmacokinetics. J Pharmacokinet Pharmacodyn. 2018;45:577\u201392.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1063_CR29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1208\/s12248-011-9267-8","volume":"13","author":"L Kagan","year":"2011","unstructured":"Kagan L, Gershkovich P, Wasan KM, Mager DE. Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone\u00ae): pooled analysis of published data. AAPS J. 2011;13:255\u201364.","journal-title":"AAPS J"},{"issue":"4\u20135","key":"1063_CR30","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/bdd.2229","volume":"41","author":"JB Lee","year":"2020","unstructured":"Lee JB, Zhou S, Chiang M, Zang X, Kim TH, Kagan L. Interspecies prediction of pharmacokinetics and tissue distribution of doxorubicin by physiologically-based pharmacokinetic modeling. Biopharm Drug Dispos. 2020;41(4\u20135):192\u2013205.","journal-title":"Biopharm Drug Dispos"},{"issue":"1","key":"1063_CR31","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.xphs.2023.10.022","volume":"113","author":"X Zang","year":"2024","unstructured":"Zang X, Kagan L. Physiologically-based modeling and interspecies prediction of cisplatin pharmacokinetics. J Pharm Sci. 2024;113(1):158\u201366.","journal-title":"J Pharm Sci"},{"key":"1063_CR32","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2165\/11594420-000000000-00000","volume":"50","author":"C Ghobadi","year":"2011","unstructured":"Ghobadi C, Johnson TN, Aarabi M, Almond LM, Allabi AC, Rowland-Yeo K, et al. Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance. Clin Pharmacokinet. 2011;50:809\u201322.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1063_CR33","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00228-020-03072-y","volume":"77","author":"W Wu","year":"2021","unstructured":"Wu W, Ke M, Ye L, Lin C. Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment. Eur J Clin Pharmacol. 2021;77(7):989\u201398.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"1063_CR34","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11095-024-03664-8","volume":"41","author":"J Adiwidjaja","year":"2024","unstructured":"Adiwidjaja J, Spires J, Brouwer KL. Physiologically Based Pharmacokinetic (PBPK) Model Predictions of Disease Mediated Changes in Drug Disposition in Patients with Nonalcoholic Fatty Liver Disease (NAFLD). Pharm Res. 2024;41(3):441\u201362.","journal-title":"Pharm Res"},{"issue":"4","key":"1063_CR35","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1124\/dmd.122.001129","volume":"51","author":"PJ De Sutter","year":"2023","unstructured":"De Sutter PJ, De Cock P, Johnson TN, Musther H, Gasthuys E, Vermeulen A. Predictive performance of physiologically based pharmacokinetic modelling of beta-lactam antibiotic concentrations in adipose, bone, and muscle tissues. Drug Metab Dispos. 2023;51(4):499\u2013508.","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"1063_CR36","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/jcph.505","volume":"55","author":"EK Chung","year":"2015","unstructured":"Chung EK, Cheatham SC, Fleming MR, Healy DP, Shea KM, Kays MB. Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients. J Clin Pharmacol. 2015;55(8):899\u2013908.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"1063_CR37","doi-asserted-by":"publisher","first-page":"7691","DOI":"10.3390\/nu7095360","volume":"7","author":"M Bhaswant","year":"2015","unstructured":"Bhaswant M, Poudyal H, Mathai ML, Ward LC, Mouatt P, Brown L. Green and black cardamom in a diet-induced rat model of metabolic syndrome. Nutrients. 2015;7(9):7691\u2013707.","journal-title":"Nutrients"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01063-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-025-01063-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01063-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T13:51:41Z","timestamp":1751637101000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-025-01063-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["1063"],"URL":"https:\/\/doi.org\/10.1208\/s12248-025-01063-4","relation":{},"ISSN":["1550-7416"],"issn-type":[{"type":"electronic","value":"1550-7416"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"20 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"78"}}